Keyword: Agios Pharmaceuticals
For Agios, just running a global randomized phase 3 trial in a tough-to-treat bile duct cancer was a major milestone. The fact that it was positive has the company over the moon.
Marion Dorsch, Chief Scientific Officer, Blueprint Medicines
Jackie Fouse has been a prime CEO candidate since leaving Celgene, and it’s Agios that finally gets to claim her as its next skipper.
Infinity, Savara and Sarepta are among the highest paying companies in the country, a new list reveals.
Agios Pharmaceuticals has scored its first FDA nod for a wholly-owned medicine, Tibsovo.